ProCE Banner Activity

New Targeted Therapies for HER2-Positive Metastatic Breast Cancer: Downloadable Slides

Slideset Download
Expert slides from CCO workshops on HER2-targeted agents for HER2-positive metastatic breast cancer, including CNS metastases and HER2-low disease.

Released: September 23, 2020

Expiration: September 22, 2021

Share

Faculty

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen

Faculty Disclosure

Primary Author

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts